Receptor activator of NF-κB ligand protein expression in UMR-106 cells is differentially regulated by parathyroid hormone and calcitriol

Journal of Cellular Biochemistry

Volumn 95, Issue 5, 2005, Pages 1029-1041

  Dossing, Debra A ^a   Stern, Paula H ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Calcitriol; Osteoblastic cell; Parathyroid hormone; Receptor activator of NF B ligand

Indexed keywords

ANTIBODY; CALCITRIOL; CYCLIC AMP; FORSKOLIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL LYSATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HORMONE ACTION; NONHUMAN; OSTEOBLAST; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BONE NEOPLASMS; CALCITRIOL; CALCIUM CHANNEL AGONISTS; CARRIER PROTEINS; CYCLIC AMP; DRUG COMBINATIONS; FORSKOLIN; GLYCOSYLATION; IMMUNOASSAY; LIGANDS; MEMBRANE GLYCOPROTEINS; NF-KAPPA B; OSTEOSARCOMA; PARATHYROID HORMONE; PROTEIN MODIFICATION, TRANSLATIONAL; RANK LIGAND; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 26444486042     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20470     Document Type: Article

References (48)

1. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L. 1997. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179.
2. Broadus AE. 1999. Mineral balance and homeostasis. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Philadelphia: Lippincott Williams and Wilkins. p. 74-80.
3. Buckley KA, Hipskind RA, Gartland A, Bowler WB, Gallagher JA. 2002. Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-κB ligand. Bone 31:582-590.
4. Catalano RD, Kyriakou T, Chen J, Easton A, Hillhouse EW. 2003. Regulation of corticotropin-releasing hormone type 2 receptors by multiple promoters and alternative splicing: Identification of multiple splice variants. Mol Endocrinol 17:395-410.
5. Dossing DA, Stern PH. 2003. Parathyroid hormone and forskolin regulate RANKL mRNA expression in UMR-106 osteoblastic cells through a cycloheximide-inhibitable mechanism: Evidence for an intermediate factor. J Bone Min Res 18:S402.
6. Fu Q, Jilka RL, Manolagas SC, O'Brien CA. 2002. Parathyroid hormone stimulates receptor activator of NF-κB ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem 277:48868-48875.
7. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. 1998. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 188:997-1001.
8. Hofbauer LC. 1999. Osteoprotegerin ligand and osteoprotegerin: Novel implications for osteoclast biology and bone metabolism. Eur J Endocrinol 141:195-210.
9. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. 2000. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Min Res 15:2-12.
10. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. 1998. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139:4743-4746.
11. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan H-L, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia X-Z, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ. 1999. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Nat Acad Sci 96:3540-3545.
12. Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA. 2004. PTH differentially regulates expression of RANKL and OPG. J Bone Min Res 19:235-244.
13. Ikeda T, Kasai M, Utsuyama M, Hirokawa K. 2001. Determination of three isoforms of the receptor activator of nuclear factor-κB ligand and their differential expression in bone and thymus. Endocrinology 142:1419-1426.
14. Ikeda T, Kasai M, Suzuki J, Kuroyama H, Seki S, Utsuyama M, Hirokawa K. 2003. Multimerization of the receptor activator of nuclear factor-κ ligand (RANKL) isoforms and regulation of osteoclastogenesis. J Biol Chem 278:47217-47222.
15. Itani OA, Campbell JR, Herrero J, Snyder PM, Thomas CP. 2003. Alternate promoters and variable splicing lead to hNedd4-2 isoforms with a C2 domain and varying number of WW domains. Am J Physiol 285:F916-F929.
16. Ito S, Wakabayashi K, Ubukata O, Hayashi S, Okada F, Hata T. 2002. Crystal structure of the extracellular domain of mouse RANK ligand at 2.2 Å resolution. J Biol Chem 277:6631-6636.
17. Itoh K, Udagawa N, Matsuzaki K, Takami M, Amano H, Shinki T, Ueno Y, Takahashi N, Suda T. 2000. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. J Bone Min Res 15:1766-1775.
18. Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, Nishihara T, Takahashi N, Suda T. 1999. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 163:434-442.
19. Kanamaru F, Iwai H, Ikeda T, Nakajima A, Ishikawa I, Azuma M. 2004. Expression of membrane-bound and soluble receptor activator of NF-κB ligand (RANKL) in human T cells. Immunol Lett 94:239-246.
20. 3 augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. Biochem Biophys Res Commun 290:650-655.
21. 3 supports osteoclastogenesis via functional vitamin D response element of human RANKT, gene promoter. J Cell Biochem 89:771-777.
22. Kondo H, Guo J, Bringhurst FR. 2002. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and oteoprotegerin mRNAs by marrow stromal cells. J Bone Min Res 17:1667-1679.
23. Kong Y-Y, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323.
24. Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y-X, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
25. Lam J, Nelson CA, Ross FP, Teitelbaum SL, Fremont DH. 2001. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest 108:971-979.
26. Lee SK, Lorenzo JA. 1999. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation. Endocrinology 140:3552-3561.
27. Lee S-K, Lorenzo JA. 2002. Regulation of receptor activator of nuclear factor-kB ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase A pathway in murine bone marrow cultures. Bone 31:252-259.
28. Lerner UH. 2004. New molecules in the tumor necrosis factor ligand and receptor superfamilies with importance for physiological and pathological bone resorption. Crit Rev Oral Biol Med 15:64-81.
29. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
30. Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, Schlöndorff J, Tempst P, Choi Y. 1999. Evidence for a role of a tumor necrosis factor-a (TNF-a)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 274:13613-13618.
31. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE. 2001. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142:4047-4054.
32. Miyazaki T, Matsunaga T, Miyazaki S, Hokari S, Komoda T. 2004. Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats. J Cell Biochem 93:503-512.
33. Nagai M, Sato N. 1999. Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. Biochem Biophys Res Commun 257:719-723.
34. Nagai M, Kyakumoto S, Sato N. 2000. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem Biophys Res Commun 269:532-536.
35. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K. 1998. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253:395-400.
36. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H. 2000. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-κB ligand: Modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 275:768-775.
37. Notoya M, Otsuka E, Yamaguchi A, Hagiwara H. 2004. Runx-2 is not essential for the vitamin D-regulated expression of RANKL and osteoprotegerin in osteoblastic cells. Biochem Biophys Res Commun 324:655-660.
38. Seth P, Mahajan VS, Chauhan SS. 2003. Transcription of human cathepsin L mRNA species hCATL B from a novel alternative promoter in the first intron of its gene. Gene 321:83-91.
39. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. 1999. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345-357.
40. Suzuki J, Ikeda T, Kuroyama H, Seki S, Kasai M, Utsuyama M, Tatsumi M, Uematsu H, Hirokawa K. 2004. Regulation of osteoclastogenesis by three human RANKL isoforms expressed in NIH3T3 cells. Biochem Biophys Res Commun 314:1021-1027.
41. Takahashi N, Udagawa N, Suda T. 1999. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 256:449-455.
42. Tsukii K, Shima N, Mochizuki S, Yamaguchi K, Kinosaki M, Yano K, Shibata O, Udagawa N, Yasuda H, Suda T, Higashio K. 1998. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1α,25- dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun 246:337-341.
43. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T. 2000. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141:3478-3484.
44. Willard D, Chen W-J, Barrett G, Blackburn K, Bynum J, Consler T, Hoffman C, Home E, Iannone MA, Kadwell S, Parham J, Ellis B. 2000. Expression, purification, and characterization of the human receptor activator of NF-κB ligand (RANKL) extracellular domain. Protein Expr Purif 20:48-57.
45. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS III, Frankel WN, Lee SY, Choi Y. 1997. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272:25190-25194.
46. Xu J, Tan JW, Huang L, Gao X-H, Laird R, Liu D, Wysocki S, Zheng MH. 2000. Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-κB ligand. J Bone Min Res 15:2178-2186.
47. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Nat Acad Sci 95:3597-3602.
48. Zennaro M-C, Le Menuet D, Lombes M. 1996. Characterization of the human mineralcorticoid receptor gene 5′-regulatory region: Evidence for differential hormonal regulation of two alternative promoters via nonclassical mechanisms. Mol Endocrinol 10:1549-1560.